Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncocyte Corp (NQ: OCX )

2.670 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncocyte Corp

< Previous 1 2 3 4 Next >
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024
OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Penny Stocks That Insiders Are Buying
Penny stocks are a risky business but following the insiders to your next trade can alleviate some of the risks; these are the three hottest insider buys. 
Via MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning! 
Via InvestorPlace
OncoCyte's Earnings: A Preview
Via Benzinga
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
Via ACCESSWIRE
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage
Via ACCESSWIRE
Earnings Scheduled For November 12, 2024
Via Benzinga
What to Expect from OncoCyte's Earnings
Via Benzinga
OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024
OCX stock results show that OncoCyte beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
Via AB Newswire
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
OncoCyte's Innovative Approach: Potential in Precision Diagnostics 
Via News Direct
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For... 
Via TheNewswire.com
4 Analysts Assess OncoCyte: What You Need To Know
Via Benzinga
Oncocyte Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Top 3 Health Care Stocks That May Collapse In Q2
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning! 
Via InvestorPlace
Earnings Scheduled For April 12, 2024
Companies Reporting Before The Bell • Progressive (NYSE:PGR) is projected to report quarterly earnings at $3.17 per share on revenue of $17.43 billion. 
Via Benzinga
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. 
Via Benzinga
Oncocyte Regains Compliance With Nasdaq Listing Requirements
Via ACCESSWIRE
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.